☆ 4.6 Review

Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future

JOURNAL OF INFLAMMATION RESEARCH (2021)

Related references

Note: Only part of the references are listed.

Article Critical Care Medicine

Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019 The Ivermectin in COVID Nineteen Study

Juliana Cepelowicz Rajter et al.

Summary: Ivermectin treatment was associated with lower mortality in COVID-19 patients, especially those with severe pulmonary involvement, suggesting its potential effectiveness in reducing mortality in hospitalized COVID-19 patients. Randomized controlled trials are needed to confirm these findings.

CHEST (2021)

Add to Collection

Article Cell Biology

Inflammasome formation in the lungs of patients with fatal COVID-19

Stefano Toldo et al.

Summary: The study revealed intense expression of the inflammasome, particularly in leukocytes, within the lungs of all fatal COVID-19 patients. The number of ASC inflammasome specks per high power fields was significantly higher in the lungs of COVID-19 patients compared to controls. This suggests a potential molecular link between viral infection and cytokine release syndrome in fatal COVID-19 pneumonia.

INFLAMMATION RESEARCH (2021)

Add to Collection

Review Cell Biology

Immunobiology and immunotherapy of COVID-19: A clinically updated overview

Abdolreza Esmaeilzadeh et al.

Summary: This paper reviews the immunopathogenesis of COVID-19 and the immune response to SARS-CoV-2, highlighting the importance of an effective immune response against the virus. Various methods, including regulation of the immune response and inhibition of viral replication, can be applied to improve the immune response and develop potential immunotherapies.

JOURNAL OF CELLULAR PHYSIOLOGY (2021)

Add to Collection

Article Virology

The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells

Shutoku Matsuyama et al.

Summary: The study found that the inhaled corticosteroid ciclesonide can inhibit the replication of coronaviruses, including SARS-CoV-2, with potential use in treating COVID-19. Ciclesonide also successfully suppressed the replication of 15 resistant mutants, making it a promising broad-spectrum antiviral drug.

JOURNAL OF VIROLOGY (2021)

Add to Collection

Review Immunology

Regulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors

Koji Onomoto et al.

Summary: RLRs are RNA sensor molecules that play essential roles in innate antiviral immunity by inducing downstream signaling via interactions with various host and viral factors. The signaling mediated by RLRs is regulated by interactions with endogenous RNAs and host proteins, and deregulation can lead to autoimmune and autoinflammatory disorders.

CELLULAR & MOLECULAR IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients

Tamara S. Rodrigues et al.

Summary: The active NLRP3 inflammasome in response to SARS-CoV-2 infection is associated with disease severity in COVID-19 patients, with higher levels of IL-18 and Casp1p20 correlating with poor clinical outcomes. These findings suggest that inflammasomes may serve as markers of disease severity and potential therapeutic targets for COVID-19.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results

Summary: The authors of the study reported the interim results of using four repurposed antiviral drugs (remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a) in hospitalized COVID-19 patients. The study showed that these drug regimens had little or no effect on overall mortality, initiation of ventilation, and duration of hospital stay.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

A. C. Kalil et al.

Summary: Combination treatment with baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation. The combination was associated with fewer serious adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

Carlos Salama et al.

Summary: Among hospitalized patients with Covid-19 pneumonia not on mechanical ventilation, tocilizumab reduced the risk of progression to mechanical ventilation or death, but did not improve overall survival. There were no new safety concerns identified.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

V. A. Simonovich et al.

Summary: There were no significant differences observed in clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo in the treatment of severe Covid-19 pneumonia. The study results indicate that both groups had similar clinical outcomes and mortality rates after 30 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Immunology

Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia

Masoud Solaymani-Dodaran et al.

Summary: The study found that adding Favipiravir to the treatment protocol did not reduce ICU admissions, intubations, or in-hospital mortality compared to the Lopinavir/Ritonavir regimen. There were also no significant differences in time to clinical recovery and length of hospital stay between the two treatment groups.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

Add to Collection

Review Medicine, General & Internal

Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19 A Systematic Review and Meta-analysis

Perrine Janiaud et al.

Summary: Convalescent plasma treatment showed no significant decrease in all-cause mortality or benefit for other clinical outcomes compared to placebo or standard of care. The certainty of the evidence ranged from low to moderate for all-cause mortality and remained low for other outcomes.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19 A Randomized Clinical Trial

Eduardo Lopez-Medina et al.

Summary: The study found that a 5-day course of ivermectin did not significantly improve the time to resolution of symptoms in adults with mild COVID-19, and does not support its use for treatment of mild COVID-19. Larger trials may be needed to understand the effects of ivermectin on other clinically relevant outcomes.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Review Infectious Diseases

COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients

Jennifer A. Belsky et al.

Summary: Severe COVID-19 caused by SARS-CoV-2 has a greater impact on immunocompromised patients such as cancer and solid organ transplant recipients, leading to higher comorbidities and poorer hospital outcomes. However, hematopoietic cell transplant recipients and pediatric cancer patients tend to have clinical presentations and outcomes similar to the general population.

JOURNAL OF INFECTION (2021)

Add to Collection

Article Medicine, General & Internal

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

I. O. Rosas et al.

Summary: In this randomized trial involving hospitalized patients with severe Covid-19 pneumonia, the use of tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

Anthony C. Gordon et al.

Summary: Interleukin-6 receptor antagonists tocilizumab and sarilumab were found to improve outcomes, including survival, in critically ill patients with Covid-19 receiving organ support in ICUs according to an ongoing international trial. The efficacy of these treatments has been confirmed, with patients benefiting from the therapy.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Respiratory System

Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19

Fasihul A. Khan et al.

Summary: Through systematic review and meta-analysis, tocilizumab was associated with a lower relative risk of mortality in COVID-19 patients, but effects on other outcomes were inconclusive. Current evidence for the efficacy of anakinra, siltuximab or sarilumab in COVID-19 is insufficient, with further studies urgently needed for conclusive findings.

THORAX (2021)

Add to Collection

Article Hematology

Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies

Preethi Jeyaraman et al.

Summary: This retrospective multicentre study analyzed the 14-day mortality in 33 patients with hematological malignancies who received convalescent plasma therapy for severe Covid-19. The study found that patients who received plasma therapy early had a shorter duration of hospitalization. The overall mortality rate was 45.5%, with no significant impact of disease status, active therapy, or comorbidities on mortality.

TRANSFUSION AND APHERESIS SCIENCE (2021)

Add to Collection

Article Virology

Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19

Monika Maria Biernat et al.

Summary: The use of convalescent plasma in patients with hematological malignancies and COVID-19 can improve overall survival, reduce the severity of infection, and accelerate recovery.

VIRUSES-BASEL (2021)

Add to Collection

Article Medicine, General & Internal

Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study

Robert Challen et al.

Summary: The study found that the mortality hazard ratio associated with infection with VOC-202012/1 compared with previously circulating variants was 1.64, indicating an increase in deaths from 2.5 to 4.1 per 1000 detected cases in comparatively low risk group of covid-19 patients in the community. This suggests that infection with VOC-202012/1 may lead to substantial additional mortality compared with previously circulating variants, impacting healthcare capacity planning and control policies.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Immunology

High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China

Wei Cao et al.

Summary: This study suggests that high-dose IVIg administered to severe COVID-19 patients within 14 days of onset is associated with reduced 28-day mortality, particularly in those without comorbidities or treated early in the disease course.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani et al.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Peter W. Horby et al.

Summary: Convalescent plasma therapy did not improve survival or other clinical outcomes in hospitalized COVID-19 patients.

LANCET (2021)

Add to Collection

Review Infectious Diseases

Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis

Qiu Wei et al.

Summary: The study suggests that tocilizumab treatment is associated with a lower risk of mortality and reduced need for mechanical ventilation among COVID-19 patients. Tocilizumab may have a substantial effectiveness in reducing mortality, especially in critical cases, providing up-to-date evidence of its potential therapeutic role in COVID-19 management.

INFECTIOUS DISEASES OF POVERTY (2021)

Add to Collection

Article Medicine, General & Internal

Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19

Brian T. Garibaldi et al.

Summary: This comparative effectiveness research study showed that the receipt of remdesivir was associated with faster clinical improvement in a cohort of predominantly non-White patients with COVID-19. Additionally, the combination of remdesivir and corticosteroids did not reduce the time to death compared with remdesivir administered alone.

JAMA NETWORK OPEN (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19 The TOGETHER Randomized Clinical Trial

Gilmar Reis et al.

Summary: This randomized clinical trial did not find any significant benefit in reducing COVID-19-associated hospitalization or other secondary clinical outcomes with hydroxychloroquine or lopinavir-ritonavir among high-risk outpatients.

JAMA NETWORK OPEN (2021)

Add to Collection

Article Rheumatology

Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study

Giulio Cavalli et al.

Summary: IL-1 inhibition was associated with reduced mortality in patients with COVID-19 and hyperinflammation, while IL-6 inhibition showed effectiveness in patients with high C-reactive protein concentrations. Both IL-1 and IL-6 inhibition were effective in patients with low lactate dehydrogenase concentrations.

LANCET RHEUMATOLOGY (2021)

Add to Collection

Article Rheumatology

Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry

Milena Gianfrancesco et al.

ANNALS OF THE RHEUMATIC DISEASES (2020)

Add to Collection

Review Immunology

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China

Wen Zhang et al.

CLINICAL IMMUNOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry

Erica J. Brenner et al.

GASTROENTEROLOGY (2020)

Add to Collection

Article Immunology

Interferon-α2b Treatment for COVID-19

Qiong Zhou et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Engineering, Multidisciplinary

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

Qingxian Cai et al.

ENGINEERING (2020)

Add to Collection

Article Medicine, General & Internal

Remdesivir for the Treatment of Covid-19-Final Report

John H. Beigel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

B. Cao et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Anesthesiology

Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-Protocol and statistical analysis plan

Marie Warrer Petersen et al.

ACTA ANAESTHESIOLOGICA SCANDINAVICA (2020)

Add to Collection

Review Immunology

Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution!

Alan A. Nguyen et al.

CLINICAL IMMUNOLOGY (2020)

Add to Collection

Article Microbiology

A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19

Effat Davoudi-Monfared et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)

Add to Collection

Article Infectious Diseases

Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19

Samia Arshad et al.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)

Add to Collection

Review Immunology

Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies

Yujun Tang et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Hematology

Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19

Thomas Hueso et al.

BLOOD (2020)

Add to Collection

Article Infectious Diseases

The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial

Naser Gharebaghi et al.

BMC INFECTIOUS DISEASES (2020)

Add to Collection

Article Medicine, General & Internal

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

David R. Boulware et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Steroids in COVID-19: An overview

Kshitij Chatterjee et al.

CLEVELAND CLINIC JOURNAL OF MEDICINE (2020)

Add to Collection

Review Chemistry, Multidisciplinary

Repurposing of Kinase Inhibitors for Treatment of COVID-19

Ellen Weisberg et al.

PHARMACEUTICAL RESEARCH (2020)

Add to Collection

Letter Medicine, Research & Experimental

Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial

Spoorthy Kulkarni et al.

TRIALS (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19 A Randomized Clinical Trial

Pierre-Francois Dequin et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19 The CoDEX Randomized Clinical Trial

Bruno M. Tomazini et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19 The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial

Derek C. Angus et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 A Meta-analysis

Jonathan A. C. Sterne et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Peter W. Horby et al.

LANCET (2020)

Add to Collection

Letter Oncology

Imatinib is not a potent anti-SARS-CoV-2 drug

Helong Zhao et al.

LEUKEMIA (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study

Sean T. H. Liu et al.

NATURE MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Peter Horby et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

John H. Stone et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, Research & Experimental

Efficacy of dexamethasone treatment for patients with the acute respiratory distress syndrome caused by COVID-19: study protocol for a randomized controlled superiority trial

Jesus Villar et al.

TRIALS (2020)

Add to Collection

Article Medicine, General & Internal

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

Anup Agarwal et al.

BMJ-BRITISH MEDICAL JOURNAL (2020)

Add to Collection

Article Physiology

Beta-Adrenergic Receptor Stimulation Modulates the Cellular Proarrhythmic Effects of Chloroquine and Azithromycin

Henry Sutanto et al.

FRONTIERS IN PHYSIOLOGY (2020)

Add to Collection

Article Infectious Diseases

Efficacy Evaluation of Early, Low-Dose, Short-Term Corticosteroids in Adults Hospitalized with Non-Severe COVID-19 Pneumonia: A Retrospective Cohort Study

Qiang Li et al.

INFECTIOUS DISEASES AND THERAPY (2020)

Add to Collection

Article Medicine, General & Internal

Interferon therapy for COVID-19 and emerging infections: Prospects and concerns

Leonard H. Calabrese et al.

CLEVELAND CLINIC JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19 A Randomized Clinical Trial

Wesley H. Self et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Review Medicine, General & Internal

Cytokine Storm

David C. Fajgenbaum et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

Carl Randall Harrell et al.

ANALYTICAL CELLULAR PATHOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19

V Spagnuolo et al.

SCIENTIFIC REPORTS (2020)

Add to Collection

Review Multidisciplinary Sciences

A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment

Ramy Mohamed Ghazy et al.

SCIENTIFIC REPORTS (2020)

Add to Collection

Article Cell Biology

Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients

Srinivasa Reddy Bonam et al.

CELL REPORTS MEDICINE (2020)

Add to Collection

Article Hematology

Mechanisms of action of intravenous immunoglobulins in autoimmune and inflammatory diseases

J Bayry et al.

TRANSFUSION CLINIQUE ET BIOLOGIQUE (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.